doi: 10.1002/hep.29238 201 FangYJiLZhuCXiaoYZhangJLuJet al
The willingness to keep taking medication can be influenced by the symptoms (or lack of) of the condition being treated
blinding of participants, healthcare providers, data collectors, outcome assessors, data analysts
These symptoms can lead to reduced fluid intake and increased fluid loss, both of which concentrate the urine and may increase the risk of crystal formation and kidney stone development
Treatment with HPE reduces hepatic fibrosis and early cirrhosis and has anti-inflammatory and anti-oxidant potentials 24
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale